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Abstract objective To describe the impact of antiretroviral therapy (ART) on mortality rates among adults
participating in an HIV community cohort study in north-west Tanzania.
methods Serological and demographic surveillance rounds have been undertaken in a population of
approximately 30 000 people since 1994. Free HIV care including ART has been available since 2005.
Event history analysis was used to compare mortality rates among HIV-negative and HIV-positive adults
in the 5-year period before and after the introduction of ART. Crude and adjusted hazard ratios were
calculated using exponential regression models. Interaction between time period and HIV status was
assessed to investigate whether there was a non-linear relationship between these two variables.
results Male and female mortality patterns varied over the pre- and post-ART period. In women, the
crude death rate fell for both HIV negatives and HIV positives hazard rate ratio (HRR = 0.71; 95%CI
0.51–0.99 and HRR = 0.68; 95%CI: 0.46–0.99, respectively). For men, the mortality among the
HIV negatives increased (HRR = 1.47; 95%CI: 1.06–2.03) while the decline in mortality among the
HIV positives (HRR = 0.77; 95%CI 0.52–1.13) was not statistically significant. The largest decrease in
HIV-positive mortality over the two periods was among the 30- to 44-year-old age group for women and
among the 45- to 59-year-old age group for men.
conclusion There has been a modest effect on mortality in the study population following the
introduction of free ART 5 years ago. Improving access to treatment and placing greater focus on
retaining individuals on treatment are essential if the full potential of treatment for reducing HIV-related
mortality is to be realised.
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Background
In recent years, the availability of antiretroviral therapy
(ART) has dramatically increased in sub-Saharan Africa,
with 4 million people estimated to be receiving treatment
by the end of 2008 (WHO 2009), representing an
increase of 300% from December 2005 (WHO 2006). In
Tanzania, national-level estimates of ART coverage,
defined as the proportion of those in need of treatment
who were receiving ART, increased from 18% to 31%
between 2006 and 2007 (WHO 2008), although these figures
mask substantial regional variations (Somi et al. 2011a).
Despite the apparent success in bringing HIV treatment
to millions of Tanzanians, the national programme has
faced numerous challenges, particularly in terms of
achieving high rates of patient retention after the initia-
tion of treatment. Data from 88 817 people attending 101
ART clinics in Tanzania suggest that the cumulative
proportion of patients who are no longer in follow-up
within 2 years of treatment initiation is 40% for men and
34% for women (Somi et al. 2011b). Among those with
known outcomes, mortality is strongly associated with
CD4 count at treatment initiation, with those starting ART
with a CD4 count of <50 ⁄ll having 2.19 (95%CI: 2.08–
2.67) times the hazard of death compared with those
starting treatment with a CD4 count between 50 and
200 U ⁄ l (Somi et al. 2011b).
One of the most important measures of the success of
an ART programmes is its impact on HIV-related mortality
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at the population level. Studies in Malawi and Ethiopia
have documented declines in mortality after the introduction
of ART, using death registers, coffin sales and burial
surveillance (Reniers et al. 2009; Mwagomba et al. 2010).
HIV community-level cohort studies that include demo-
graphic surveillance systems (DSS) and verbal autopsy data
are even better placed to directly measure the impact of
ART on mortality in the population from the time that
treatment first became available. In a DSS study in the
north of Malawi, declines in the overall mortality rates
among adults were observed within 8 months of free ART
becoming available, with mortality reduced by 35%
(adjusted rate ratio = 0.65; 0.46–0.92) in adults living near
the main road, where mortality prior to ART availability
had been highest (Jahn et al. 2008). A later study in the
same setting detected a decline of 32% in the AIDS-specific
mortality rate in the 2 years after the introduction of ART
at a clinic in the study area, compared with the 3 years
before, with estimated treatment coverage of approxi-
mately 70% (Floyd et al. 2010). In a South African cohort
study that incorporated DSS data, HIV-related age-
standardised mortality declined significantly, from 22.5 to
17.6 per 1000 person-years in women 25–49 years of age
(P < 0.001) and from 26.5 to 18.7 per 1000 person-years
in men 25–49 years of age (P < 0.001) between 2002 and
2003, before ART availability, and 2004–2006, after ART
was introduced (Herbst et al. 2009).
In Kisesa in the north-west of Tanzania, an open HIV
cohort study has been monitoring the dynamics of the HIV
epidemic since 1994. In this setting, the proportion of the
HIV-infected population in need of ART has been esti-
mated as 26% in men and 23% in women in 2004, just
before the start of the national HIV treatment programme
(Zaba 2012), with coverage of treatment at 3% by the
end of 2007, 2 years after the introduction of free ART in
the regional referral hospital through the national HIV
treatment programme (Wringe et al. 2012), since then
coverage has increased with the introduction in 2008 of
ART in the local health centre. The aim of this paper was
to measure the impact of antiretroviral therapy provision
on trends in adult mortality in this setting.
Methods
Study setting
The Kisesa cohort study has been monitoring the dynamics
of the HIV epidemic since 1994 through regular serolog-
ical, behavioural and demographic surveillance among a
population of approximately 30 000 individuals living in
six rural villages and a trading centre in a rural area of
north-west Tanzania. The study area is located approxi-
mately 20 km from Mwanza, the country’s second city,
bordering Lake Victoria. Most people are subsistence
farmers and economic activities include petty trade of milk
and vegetables in the trading centre (Mwaluko et al. 2003).
There are six health facilities in the study area, including
one health centre in the trading centre.
Cohort study methods
Demographic rounds, collecting information on births,
deaths and migration, take place at each household
approximately twice per year as part of the DSS. Serolog-
ical surveillance rounds take place within each village
approximately every 3 years among consenting adults who
were resident in the ward at the preceding demographic
surveillance round. The serological surveillance rounds
include HIV testing for research purposes without results
disclosure and a detailed questionnaire on fertility, sexual
behaviour and use of health services. Participants have
access to a free health clinic for themselves and all family
members, and since the 2000–2001 round, they can
undergo voluntary counselling and testing (VCT) if they
wish to know their HIV status.
A dried blood spot taken from a finger prick is tested for
HIV at the National Institute of Medical Research in
Mwanza, using Vironostika HIV-MIXT and Enzygnost
HIV1 ⁄HIV2. Samples are considered to be HIV positive if
both ELISA results are reactive and any discrepant results
are re-tested by repeating the two ELISA tests. Any samples
still returning a discrepant result are excluded from analysis.
Participation at the serological surveys has declined
slightly over time from 74% to 61% between 1994 ⁄5 and
2006 ⁄7 (Urassa et al. 2010). HIV prevalence at the 2006–
2007 serological surveillance round was 6% among men
and women. HIV incidence was 1.1% in 2000–2003
(Wambura et al. 2007).
Provision of HIV services
A permanent VCT service has been available to the study
population since early 2005 at the health centre in the
trading centre. In addition, temporary VCT services have
been provided in each village during the serological
surveys. VCT uptake during the serological surveys was
<1% in 2000–2001, 10% in 2003–2004 and 17% in
2006–2007 (Isingo 2012).
Free HIV care and treatment, including ART, first
became available to the study population at the begin-
ning of 2005 through the national HIV programme. HIV
care was initially available at the zonal and regional
referral hospitals in Mwanza and was subsequently rolled
out to district hospitals and health centres. Free ART has
Tropical Medicine and International Health volume 17 no 8 pp e58–e65 august 2012
M. Marston et al. Adult mortality in rural Tanzania
ª 2012 Blackwell Publishing Ltd e59
been available at the Kisesa health centre in the trading
centre since September 2008. Individuals receiving a
positive HIV diagnosis at the VCT centre in the health
centre or the serological surveys are referred to the
closest ART clinic for a clinical and immunological
assessment to determine their eligibility to start HIV
treatment. Money is provided to cover transportation
costs from the Kisesa health centre to the ART clinic in
Mwanza and diagnosed persons are linked to a local
home-based care organisation for additional support if
they wish (Nsigaye et al. 2009).
Data from referral forms, along with attendance data
from the VCT services and the ART clinic, have been
anonymously linked to the cohort data since 2005,
enabling the number of HIV-infected individuals in the
study population who initiated ART between January
2005 and December 2009 to be estimated.
Statistical analysis
Subjects entered into follow-up at the date of their
participation in the first serological surveillance round, or
the date that they entered the cohort through the DSS, if
they did not attend the first sero-survey. Exit was because
of out-migration, censoring at the last DSS round they were
seen or death, the last round used took place at the end of
2009. Subjects who entered the cohort after the 2006–2007
serological surveillance round were excluded from the
analysis, as they would not yet have had an opportunity to
undergo HIV testing.
Person-years of follow-up were divided into the follow-
ing HIV status groups: (i) HIV infected, (ii) HIV negative,
(iii) unknown (for those never tested, prior to first test, and
more than 5 years after the last negative HIV test). The
HIV-positive group contained the person-years of individ-
uals after their first positive test. The HIV-negative group
contained all the person-years of follow-up for individuals
known to be HIV negative, as well as the person-years in a
fixed time interval following a negative HIV test (5 years).
It is essential to include a segment of time following on
from the last negative test, since otherwise no deaths could
be observed among the HIV negative, as their exposure
time would end at their last HIV test when they are known
to be still alive. The cut-off time selected for the post-
negative group was taken as 5 years, after that their HIV
status was classified as unknown. For sero-converters
(613), a mid-point between the last negative and first positive
test was taken and the person-years assigned accordingly.
Person-years were further split over two time periods: (i)
the 5 years prior to the introduction of ART and (ii) the
period after the introduction of ART. The introduction of
ART in Kisesa was taken as 3 March 2005.
Crude and adjusted hazard ratios were calculated using
exponential regression models. Interaction terms were used
between time period and HIV status to investigate whether
there was a non-linear relationship between the two
variables. All analyses were performed using Stata 11.1.
Ethical clearance
Ethical approval for the study was granted by the Tanza-
nian Medical Research Coordinating Committee and the
London School of Hygiene and Tropical Medicine.
Results
Overall mortality
Overall, the crude adult mortality rate among 15–59-year
olds declined by 17% (hazard rate ratio (HRR) = 0.83;
95%CI: 0.72–0.95) between the pre-ART and the post-
ART periods. This change in mortality over the two time
periods was predominantly because of a fall in female
mortality from 8.8 deaths per 1000 person-years to 6.5
deaths per 1000 person-years (HRR = 0.73; 95%CI: 0.60–
0.89). The crude male mortality rate remained similar over
the two time periods at 9.1 in the pre-ART period and 8.5
in the post-ART period (Table 1). Over the whole time
period, the crude mortality rate in those who are HIV
positive is very high compared with those who are HIV
negative, with a hazard rate ratio of 11.4 (95% CI: 8.9–
14.7) for men and 9.4 (95% CI: 7.4–12.12) for women.
Mortality by HIV status
Male and female trends in mortality vary over the pre- and
post-ART period (Tables 2 and 3). In women, the crude
death rate fell for both HIV negatives and HIV positives
(HRR = 0.71; 95%CI 0.51–0.99 and HRR = 0.68;
95%CI: 0.46–0.99, respectively). For men, the mortality
among the HIV negatives increased (HRR = 1.47; 95%CI:
1.06–2.03) while the statistical evidence for a change in
mortality among the HIV positives was inconclusive
(HRR = 0.77; 95%CI 0.52–1.13). The largest decrease in
HIV-positive mortality over the two periods was among
the 30- to 44-year-old age group for women (HRR = 0.51,
95% CI 0.31–0.86) and among the 45- to 59-year-old age
group for men (HRR = 0.46, 95% CI 0.23–0.93).
The exponential regression models (Table 4) show that
for men, the change in mortality over time is different for
those who were HIV positive compared with those who
were HIV negative with an interaction term between the
time period and HIV status of 0.48 (95% CI 0.29–0.80).
This means that while mortality among HIV-negative men
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rose slightly (HRR = 1.48; 95%CI: 1.07–2.05), among
HIV-positive men, there was evidence of borderline
significance to suggest that mortality declined
(HRR = 0.72; 95%CI: 0.48–1.06). Among women, there
was no evidence of interaction between the time period and
HIV status. The adjusted mortality rate was 13.6 (95% CI
9.5–19.3) times higher for men who were HIV positive
compared with those who were HIV negative and 10.4
times higher for women (95%CI 7.5–14.3) over the entire
period 2000–2009 (Table 4).
ART uptake
Antiretroviral therapy uptake among the study population
steadily increased between 2005 and 2009: the number of men
on treatment doubled and the number of women quadru-
pled (Table 5). ART uptake in 2009 is highest for men and
women aged between 30 and 44 years old, although the
distribution is skewed towards the younger ages for women
and towards the older ages for men. There is no evidence
of a difference between men and women in the CD4 count
or WHO stage at the time of treatment initiation.
Discussion
Adult mortality in Kisesa generally fell between 2000 and
2010, which is largely attributable to the decline in deaths
among women. There was some evidence that ART uptake
among the study population has had an impact on adult
mortality among men, since despite a slight increase in the
mortality rates among the HIV negatives, there was no
equivalent rise in the mortality among the HIV positives,
with some suggestion that it had decreased. These differ-
ences were not observed among the women, where
mortality dropped among both the HIV positives and the
HIV negatives by a similar degree. The mortality of men
with unknown HIV status appeared to fall dramatically,
which is most likely due to the changing composition of the
group. It is plausible that with the availability of ART in
the area, the incentive to participate in the serological
survey has become greater, particularly for those who
suspect that they may be infected with HIV, as VCT
services can be accessed within the village. In this case, over
time, a growing proportion of individuals with an
unknown HIV status will actually be HIV-negative indi-
viduals, and these persons will have lower mortality over
the pre- and post-ART periods.
Other HIV cohort studies in sub-Saharan Africa that
began ART roll-out at around the same time have found
stronger evidence of an impact on mortality (Herbst et al.
2009; Floyd et al. 2010; Kasamba et al. 2012). Neverthe-
less, there are important differences between each setting,
particularly in terms of access to treatment and the speed at
which decentralisation of services occurred. For residents
Table 1 Distribution of person-years and deaths with crude hazard rates
Men Women
Deaths
Person-
years
(per 1000)
Death rate
(per 1000)
Crude hazard ratios
Deaths
Person-
years
(per 1000)
Death rate
(per 1000)
Crude hazard ratios
HRR (95% CI) P-values HRR (95% CI) P-values
Period
Pre-ART 260 28.56 9.1 1 263 29.75 8.84 1
Post-ART 182 21.5 8.47 0.93 (0.77–1.12) 0.452 151 23.36 6.47 0.73 (0.60–0.89) 0.002
HIV status
Negative 149 26.82 5.56 1 150 31.03 4.83 1
Positive 106 1.68 63.11 11.36 (8.86–14.57) <0.001 111 2.43 45.64 9.44 (7.39–12.07) <0.001
Unknown 187 21.56 8.67 1.56 (1.26–1.94) <0.001 153 19.64 7.79 1.61 (1.29- 2.02) <0.001
Age group
15–29 112 27.23 4.11 1 117 26.49 4.42 1
30–44 194 15.16 12.8 3.11 (2.47–3.93) <0.001 187 17.74 10.54 2.39 (1.89–3.01) <0.001
45–59 136 7.67 17.73 4.31 (3.36–5.54) <0.001 110 8.87 12.4 2.81 (2.16–3.64) <0.001
Residence
Rural 234 26.99 8.67 1 205 27.82 7.37 1
Trading
centre
97 10.13 9.58 1.1 (0.87–1.40) 0.409 97 11.31 8.57 1.16 (0.91–1.48) 0.219
Roadside 111 12.93 8.58 0.99 (0.79–1.24) 0.933 112 13.97 8.02 1.09 (0.86–1.37) 0.472
ART, antiretroviral therapy; HRR, hazard rate ratio.
Pre-ART = before 1st Jan 2005.
Post-ART = after 1st Jan 2005.
Tropical Medicine and International Health volume 17 no 8 pp e58–e65 august 2012
M. Marston et al. Adult mortality in rural Tanzania
ª 2012 Blackwell Publishing Ltd e61
in Kisesa, ART was initially only available via a referral
from the local VCT clinics to the zonal referral hospital in
Mwanza City, approximately 20 km away. Several qual-
itative studies identified the long journey time, waiting
times at the clinic and a lack of familiarity with the city and
intimidation at the very large health facility as barriers to
attending the ART clinic at the hospital (Nsigaye et al.
2009; Roura et al. 2009; Wringe et al. 2009), explaining
the low ART coverage observed by the end of 2007
(Wringe et al. 2012). Although ART treatment became
available in the Kisesa health centre in September 2008 as
part of the government’s plans to decentralise ART, the
mortality impact from the increasing number of persons
initiating treatment is unlikely to be seen immediately. In
the other studies, ART treatment was available to partic-
ipants locally in the study area, either from the beginning
or shortly after the introduction of HIV treatment by the
national programme, which is likely to have resulted in a
much higher coverage of ART within a shorter time-frame,
enabling the effects of treatment on mortality to be
observed more quickly (Wringe et al. 2012).
This study showed that in those where the HIV status
was known, 42% of the deaths (111 ⁄261 – 43% in
women, and 106 ⁄255 – 42% in men) occurred in those
who were HIV positive, despite the fact they represented
<10% of the population, and only 6.6% of the person-
years. In the period before ART, 46% (128 ⁄279) of all
deaths occurred in HIV positive, which reduced to 38%
(89 ⁄337) following the introduction of ART. Overall, this
corresponded to 20 deaths averted in the period following
ART introduction.
Bigger changes in mortality in Kisesa may have occurred
through changes in the environment in the ward. In the last
7 years, the road from Mwanza to Kenya has been
tarmaced, and Kisesa has changed from a quiet village
producing cotton to a centre for trading rice, and a
dormitory suburb of Mwanza city. This new traffic may
account for some of the increased number of deaths in
young men.
For this analysis, we assumed that a person remains HIV
negative for 5 years after the last negative HIV test.
Changing this assumption to 2 years after the last negative
Table 2 Crude hazard rate ratios in adults aged 15–59 pre- and post-ART roll-out and HIV status for men
Men – HIV negative Men – HIV positive
Death
Person-
years
per 1000
Death
rate
Crude
RR 95% CI P-value Death
Person-
years
per 1000
Death
rate
Crude
RR 95% CI P-value
ART period
Pre-0–5 years 62 13.71 4.52 1 63 0.89 70.77 1
Post-1st period 87 13.11 6.64 1.47 (1.06–2.03) 0.021 43 0.79 54.48 0.77 (0.52–1.13) 0.186
Age grouped
15–29
Pre-0–5 years 10 7.38 1.35 1 10 0.31 31.96 1
Post-1st period 26 7.26 3.58 2.64 (1.27–5.48) 0.009 7 0.22 31.92 1.00 (0.38–2.62) 0.998
30–44
Pre-0–5 years 23 4.26 5.4 1 30 0.42 71.49 1
Post-1st Period 30 3.6 8.33 1.54 (0.90–2.65) 0.118 24 0.39 61.32 0.86 (0.50–1.47) 0.575
45–59
Pre-0–5 years 29 2.07 13.99 1 23 0.16 145.9 1
Post-1st period 31 2.24 13.83 0.99 (0.60–1.64) 0.964 12 0.18 67.19 0.46 (0.23–0.93) 0.029
Area of residence
Rural
Pre-0–5 years 35 8.93 3.92 1 30 0.47 64.01 1
Post-1st period 58 7.95 7.3 1.86 (1.22–2.83) 0.004 23 0.43 53.54 0.84 (0.49–1.44) 0.519
Urban
Pre-0–5 years 19 2.57 7.4 1 14 0.2 68.48 1
Post-1st period 14 2.62 5.35 0.72 (0.36–1.44) 0.356 10 0.18 54.94 0.80 (0.36–1.81) 0.595
Roadside
Pre-0–5 years 8 2.22 3.61 1 19 0.22 87.53 1
Post-1st period 15 2.54 5.91 1.64 (0.69–3.86) 0.260 10 0.18 56.28 0.64 (0.30–1.38) 0.258
ART, antiretroviral therapy.
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Table 3 Crude hazard rate ratios in adults aged 15–59 years in the pre- and post-ART periods and HIV status, for women
Women – HIV negative Women – HIV positive
Death
Person-
years
per 1000
Death
rate
Crude
RR 95% CI P-value Death
Person-
years
per 1000
Death
rate
Crude
RR 95% CI P-value
ART period
Pre-0–5 years 89 15.81 5.63 1 65 1.19 54.69 1
Post-1st period 61 15.22 4.01 0.71 (0.51–0.99) 0.041 46 1.24 36.99 0.68 (0.46–0.99) 0.042
Age grouped
15–29
Pre-0–5 years 17 6.67 2.55 1 18 0.51 35.3 1
Post-1st period 14 6.31 2.22 0.87 (0.43–1.77) 0.701 10 0.37 27.28 0.77 (0.36–1.67) 0.513
30–44
Pre-0–5 years 36 6.08 5.92 1 38 0.55 69.44 1
Post-1st period 24 5.66 4.24 0.72 (0.43–1.20) 0.206 24 0.67 35.66 0.51 (0.31–0.86) 0.011
45–59
Pre-0–5 years 36 3.06 11.77 1 9 0.13 68.49 1
Post-1st period 23 3.25 7.07 0.60 (0.36–1.01) 0.056 12 0.2 58.89 0.86 (0.36–2.04) 0.732
Area of residence
Rural
Pre-0–5 years 54 9.52 5.67 1 27 0.52 52.06 1
Post-1st period 32 8.51 3.76 0.66 (0.43–1.03) 0.065 16 0.52 30.55 0.59 (0.32–1.09) 0.091
Urban
Pre-0–5 years 14 3.23 4.34 1 15 0.25 59.59 1
Post-1st period 14 3.35 4.19 0.96 (0.46–2.02) 0.924 18 0.35 51.71 0.87 (0.44–1.72) 0.685
Roadside
Pre 0–5 years 21 3.07 6.85 1 23 0.42 55 1
Post-1st period 15 3.37 4.45 0.65 (0.34–1.26) 0.203 12 0.37 32.3 0.59 (0.29–1.18) 0.135
ART, antiretroviral therapy.
Table 4 Adjusted mortality hazard rate ratios using exponential regression by sex
Males Females
Hazard ratio 95% CI P-values Hazard ratio 95% CI P-values
Period
Pre-ART 1 1
Post-ART 1.48 (1.07–2.05) 0.019 0.70 (0.51–0.97) 0.034
HIV status
Negative 1 1
Positive 13.57 (9.54–19.32) <0.001 10.35 (7.49–14.30) <0.001
Unknown 2.33 (1.71–3.16) <0.001 2.00 (1.50–2.66) <0.001
Interaction between period and HIV status
Negative post-ART to pre-ART 1 1
Positive post-ART to pre-ART 0.48 (0.29–0.80) 0.005 0.85 (0.52–1.40) 0.523
Unknown post-ART to pre-ART 0.45 (0.28–0.71) 0.001 0.94 (0.58–1.51) 0.793
Area of residence
Rural 1 1
Roadside 0.97 (0.76–1.23) 0.784 1.01 (0.80–1.29) 0.908
Trading centre 0.86 (0.68–1.08) 0.189 0.90 (0.71–1.13) 0.352
Age group
15–29 1 1
30–44 2.66 (2.10–3.36) <0.001 2.34 (1.85–2.97) <0.001
45–59 3.92 (3.04–5.04) <0.001 3.29 (2.52–4.29) <0.001
ART, antiretroviral therapy.
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HIV test lowered the mortality level slightly giving 4.1 and
3.0 deaths per 1000 person-years pre- and post-ART for
women compared with 5.6 and 4.0 when using 5 years.
Similar results were found for men with the changed
assumption. Similarly, inclusion of a period of 1 year prior
to the first positive HIV test in the calculation of the HIV
positive mortality rates lowered the estimates slightly,
giving mortality rates of 65.7 and 50.5 per 1000 person-
years, pre- and post-ART, for positive men compared to
70.8 and 54.5 when excluding the period prior to the first
positive HIV test. This accords with the previously
reported low mortality in the first 2 years following sero-
conversion (Todd et al. 2007).
In conclusion, there has been a modest effect on
mortality in the study population following the introduc-
tion of free ART 5 years ago. Improving access to
treatment and placing greater focus on retaining individ-
uals on treatment are essential if the full potential of
treatment for reducing HIV-related mortality is to be
realised.
Acknowledgements
The Kisesa study is funded by the Wellcome Trust and by
the Tanzanian Ministry of Health and Social Welfare
through a grant from the Global Fund for AIDS, TB and
Malaria.
References
Floyd S, Molesworth A, Dube A et al. (2010) Population-level
reduction in adult mortality after extension of free anti-retro-
viral therapy provision into rural areas in northern Malawi.
PLoS ONE 5, e13499.
Herbst AJ, Cooke GS, Barnighausen T, Kanykany A, Tanser F &
Newell ML. (2009) Adult mortality and antiretroviral treat-
ment roll-out in rural KwaZulu-Natal, South Africa. Bulletin
of the World Health Organization 87, 754–762.
Isingo R. (2012) Trends in the uptake of voluntary counselling and
testing for HIV in rural Tanzania in the context of the scale up
of antiretroviral therapy. Tropical Medicine and International
Health 17, e15–e25.
Jahn A, Floyd S, Crampin AC et al. (2008) Population-level
effect of HIV on adult mortality and early evidence of reversal
after introduction of antiretroviral therapy in Malawi. Lancet
371, 1603–1611.
Kasamba I, Baisley K, Mayanja B, Maher D & Grosskurth H
(2012) Adult mortality before and after roll-out of antiretroviral
treatment in a developing country: a longitudinal population-
based study in rural Uganda, 1999–2009. Tropical Medicine
and International Health 17, e66–e73.
Mwagomba B, Zachariah R, Massaquoi M et al. (2010) Mortality
reduction associated with HIV ⁄AIDS care and antiretroviral
treatment in rural Malawi: evidence from registers, coffin sales
and funerals. PLoS ONE 5, e10452.
Mwaluko G, Urassa M, Isingo R, Zaba B & Boerma JT (2003)
Trends in HIV and sexual behaviour in a longitudinal study
in a rural population in Tanzania, 1994–2000. AIDS 17,
2645–2651.
Nsigaye R, Wringe A, Roura M et al. (2009) From HIV diagnosis
to treatment: evaluation of a referral system to promote and
monitor access to antiretroviral therapy in rural Tanzania.
Journal of International AIDS Society 12, 31.
Reniers G, Araya T, Davey G et al. (2009) Steep declines in
population-level AIDS mortality following the introduction of
antiretroviral therapy in Addis Ababa, Ethiopia. AIDS 23,
511–518.
Roura M, Busza J, Wringe A, Mbata D, Urassa M & Zaba B.
(2009) Barriers to sustaining antiretroviral treatment in
Kisesa, Tanzania: a follow-up study to understand attrition from
the antiretroviral program. AIDS Patient Care STDS 23, 203–
210.
Somi G, Baker-Guni E, Keogh S et al. (2011a) Using clinic and
survey data to estimate coverage of HIV care and treatment
services in Tanzania. 6th IAS Conference on HIV Pathogenesis,
Treatment and Prevention, Rome.
Somi G, Keogh S, Kilama B et al. (2011b) Low mortality risk but
high loss to follow-up among patients in the Tanzanian HIV
care and treatment programme. 6th IAS Conference on HIV
Pathogenesis, Treatment and Prevention, Rome, Abstract
number: 1981
Table 5 Characteristics of adults in the study population on ART,
at treatment initiation, by sex
Men Women
N % N %
Age group
15–29 29 13.18 150 32.05
30–44 109 49.55 233 49.79
45–59 48 21.82 51 10.90
WHO stage
1 34 15.45 55 11.75
2 38 17.27 93 19.87
3 46 20.91 75 16.03
4 9 4.09 27 5.77
CD4 group
<50 26 11.82 47 10.04
50–199 71 32.27 137 29.27
200+ 26 11.82 62 13.25
Year
2005 29 13.18 41 8.76
2006 30 13.64 69 14.74
2007 42 19.09 88 18.80
2008 55 25.00 116 24.79
2009 64 29.09 154 32.91
Total 220 100.00 468 100.00
ART, antiretroviral therapy.
Tropical Medicine and International Health volume 17 no 8 pp e58–e65 august 2012
M. Marston et al. Adult mortality in rural Tanzania
e64 ª 2012 Blackwell Publishing Ltd
Todd J, Glynn JR, Marston M et al. (2007) Time from HIV
seroconversion to death: a collaborative analysis of eight studies
in six low and middle-income countries before highly active
antiretroviral therapy. AIDS 21(Suppl 6), S55–S63.
Urassa M, Isingo R, Marston M et al. (2010) Direct evidence
of recent change in HIV prevalence and incidence in a rural
population cohort in Northern Tanzania, 1994–2007. XVIII
International AIDS Conference, Vienna.
Wambura M, Urassa M, Isingo R et al. (2007) HIV prevalence and
incidence in rural Tanzania: results from 10 years of follow-up
in an open-cohort study. Journal of Acquired Immune
Deficiency Syndromes 46, 616–623.
WHO (2006). Progess on Global Access to HIV Antiretroviral
Therapy: A Report of ‘‘3 by 5’’ and Beyond. WHO ⁄UNAIDS,
Geneva.
WHO (2008). Towards Universal Access: Scaling up Priority
HIV ⁄AIDS Interventions in the Health Sector. Progress Report
2008. WHO ⁄UNAIDS, Geneva.
WHO (2009). Towards Universal Access: Scaling up Priority
HIV ⁄AIDS Interventions in the Health Sector. Progress Report
2009. WHO ⁄UNAIDS, Geneva.
Wringe A, Roura M, Urassa M, Busza J, Athanas V & Zaba
B (2009) Doubts, denial and divine intervention: under-
standing delayed attendance and poor retention rates at a
HIV treatment programme in rural Tanzania. AIDS Care 21,
632–637.
Wringe A, Floyd S, Kazooba P et al. (2012) Antiretroviral therapy
uptake and coverage in four HIV community cohort studies in
sub-Saharan Africa. Tropical Medicine and International Health
17, e38–e48.
Zaba B. (2012) Estimating current ART need from the age
distribution of infected persons – a comparative analysis of
data from five African cohort studies. Tropical Medicine and
International Health 17, e3–e14.
Corresponding Author Milly Marston, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
Tel.: +44 (0) 207 299 4665; Fax: +44 (0) 207 299 4637; E-mail: Milly.marston@lshtm.ac.uk
Tropical Medicine and International Health volume 17 no 8 pp e58–e65 august 2012
M. Marston et al. Adult mortality in rural Tanzania
ª 2012 Blackwell Publishing Ltd e65
